A Study of Encorafenib + Binimetinib in Patients With BRAF V600-mutant Non-Small Cell Lung Cancer
A Study of Encorafenib + Binimetinib in Patients With BRAF V600-mutant Non-Small Cell Lung Cancer. Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAF V600-mutant Non-Small Cell Lung Cancer.
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT03915951
Protocol ID: C4221008
PrintDownloadOpen Plain Language Summary Result: Click here